Person profile

Public information reviewed

Paresh Patel

Role

Chief Executive Officer at Exzeo Group, Inc. (NYSE: XZO)

Board role

Director · Exzeo Group, Inc. (NYSE: XZO)

Board role

Director · REVIVA PHARMACEUTICALS HOLDINGS, INC. (OTC: RVPH)

Board role

Director · HCI Group, Inc. (OTC: HCIIP)

Board role

Chairman of the Board and Chief Executive Officer · Exzeo Group, Inc. (NYSE: XZO)

Exzeo Group, Inc. (NYSE: XZO)

Chairman of the Board and Chief Executive Officer · Current mandate

Director · Executive
Public sources
14 reviewed
Profile ownership
Not yet claimed
Last reviewed
Sep 14, 2026
View sources

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
53 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
3Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Founded Exzeo in 2020 and has served as CEO and Chairman. Also serves as Chairman and CEO of HCI since 2011. Has more than 30 years of leadership experience across technology, finance, and insurance operations including development of policy administration systems and large scale systems integration initiatives.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Board appointments

Director

REVIVA PHARMACEUTICALS HOLDINGS, INC. (OTC: RVPH)

Jan 1, 2020 – Present

Independence: Independent

Source effective: 2025-11-04 · Observed: 2026-04-25T01:08:01.515+00:00

confirmedView source

Chairman of the Board and Chief Executive Officer

Exzeo Group, Inc. (NYSE: XZO)

Current

Independence: Not independent

Source effective: 2026-04-29 · Observed: 2026-09-14T13:10:01.297131+00:00

confirmedView source

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Exzeo Group, Inc.

2020-01-01 · current

Confirmed by public sourceView source

Director

REVIVA PHARMACEUTICALS HOLDINGS, INC.

2020-01-01 · current

Confirmed by public sourceView source

Director

HCI Group, Inc.

2007-01-01 · current

Confirmed by public sourceView source

Chairman of the Board and Chief Executive Officer

Exzeo Group, Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Exzeo Group, Inc.

Open Exzeo Group, Inc. profile →

Director at Exzeo Group, Inc.

2020-01-01 → End not stated

current · source reported

Observed: 2026-09-21

Chairman and Chief Executive Officer at Exzeo Group, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-21

Chairman of the Board and Chief Executive Officer at Exzeo Group, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-21

Exzeo Group, Inc.Exzeo Group, Inc.HCI Group, Inc.HCI Group, Inc.REVIVA PHARMACEUTI…REVIVA PHARMACEUTICALS HOLDINGS, INC.Paresh Patel

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:purav-patel
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of Exzeo Group, Inc.Supported by 2 public records1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of HCI Group, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of REVIVA PHARMACEUTICALS HOLDINGS, INC.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Compensation, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Buena Vista Fund I1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Crown Reserve Acquisition Corp. I1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Exzeo Group, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · CorroboratedExecutive at HCI Group, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
Jul 28, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at REVIVA PHARMACEUTICALS HOLDINGS, INC.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Wellgistics Health, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · CorroboratedExecutive title: Chairman and Chief Executive OfficerSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · CorroboratedExecutive title: Chief Executive OfficerSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
Jul 28, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Founder and Managing Partner1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: President1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedParesh Patel is also linked to HCI as Chairman and Chief Executive Officer.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Under reviewTechnology background: not identified in the cited filing1 source
Verification
Under review
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Under reviewTechnology background reported in filings1 source
Verification
Under review
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources14 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1873951/000119312526191689/d206711ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed Sep 2, 2026

    Supports: Director at Exzeo Group, Inc. (NYSE: XZO)

  3. https://www.sec.gov/Archives/edgar/data/1400810/000119312526191649/d49080ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed Sep 2, 2026

    Supports: Director at HCI Group, Inc. (OTC: HCIIP)

  4. https://www.sec.gov/Archives/edgar/data/1873951/000119312526191689/d206711ddef14a.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 14, 2026

    Supports: Chairman and Chief Executive Officer at Exzeo Group, Inc. (NYSE: XZO) · Chairman of the Board and Chief Executive Officer at Exzeo Group, Inc. (NYSE: XZO)

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

    Supports: Executive company · Executive title

  9. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  10. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  11. https://www.sec.gov/Archives/edgar/data/1742927/000143774925033023/rvph20251029_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at REVIVA PHARMACEUTICALS HOLDINGS, INC. (OTC: RVPH)

  12. https://www.sec.gov/Archives/edgar/data/1873951/000119312526191689/d206711ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  13. https://www.sec.gov/Archives/edgar/data/1742927/000143774925033023/rvph20251029_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  14. https://www.sec.gov/Archives/edgar/data/1400810/000119312526191649/d49080ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership